ATFB
MCID: FML001
MIFTS: 67

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Familial Atrial Fibrillation

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 12 53 25 59 29 6 15 72
Atrial Fibrillation, Familial 53 25 55
Atfb 12 53
Atrial Fibrillation Autosomal Dominant 53
Autosomal Dominant Atrial Fibrillation 53
Atrial Fibrillation, Familial, 1 72
Auricular Fibrillation 25
Atrial Fibrillation 72

Characteristics:

Orphanet epidemiological data:

59
familial atrial fibrillation
Inheritance: Autosomal dominant;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050650
ICD10 via Orphanet 34 I48.9
Orphanet 59 ORPHA334
UMLS 72 C0004238 C1843687 C3468561

Summaries for Familial Atrial Fibrillation

NIH Rare Diseases : 53 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat (arrhythmia). Signs and symptoms may include dizziness, chest pain, palpitations, shortness of breath, or fainting. Affected people also have an increased risk of stroke and sudden death. While complications may occur at any age, some affected people never have associated health problems. Familial atrial fibrillation may be caused by changes (mutations) in any of various genes, some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary : Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to cardiac arrhythmia and ventricular fibrillation, paroxysmal familial, 1, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and DREAM Repression and Dynorphin Expression. The drugs Prednisolone phosphate and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

Genetics Home Reference : 25 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Wikipedia : 75 Familial atrial fibrillation is an autosomal dominant heart condition that causes disruptions in the... more...

Related Diseases for Familial Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 cardiac arrhythmia 31.7 SCN5A KCNQ1 KCNJ2 KCNE2
2 ventricular fibrillation, paroxysmal familial, 1 31.3 SCN5A NKX2-5 KCNQ1 KCNE2
3 progressive familial heart block, type ia 31.2 SCN5A GJA5
4 long qt syndrome 31.1 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2 KCNA5
5 short qt syndrome 31.0 KCNQ1 KCNJ2 KCNE2
6 syncope 30.9 SCN5A NPPA KCNQ1 KCNJ2
7 atrioventricular block 30.8 SCN5A NKX2-5 KCNQ1 KCNE2 GATA4
8 jervell and lange-nielsen syndrome 1 30.8 SCN5A SCN4B KCNQ1 KCNE2
9 patent ductus arteriosus 1 30.7 NKX2-5 GATA6 GATA4
10 long qt syndrome 1 30.7 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
11 heart septal defect 30.7 NKX2-5 GATA6 GATA4
12 atrial heart septal defect 30.6 NKX2-5 GATA6 GATA4
13 heart disease 30.3 SCN5A PITX2 NPPA NKX2-5 KCNQ1 KCNJ2
14 dilated cardiomyopathy 30.3 NKX2-5 KCNQ1 GJA5 GATA4 SCN5A NPPA
15 atrial fibrillation 29.4 SCN5A SCN4B SCN3B SCN2B NUP155 NPPA
16 atrial fibrillation, familial, 15 12.8
17 brugada syndrome 7 12.2
18 atrial fibrillation, familial, 11 11.7
19 atrial fibrillation, familial, 12 11.7
20 atrial fibrillation, familial, 13 11.7
21 atrial fibrillation, familial, 14 11.7
22 long qt syndrome 12 10.8 SCN5A KCNQ1 KCNE2
23 familial short qt syndrome 10.8 KCNQ1 KCNJ2
24 ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy 10.8 SCN5A KCNQ1 KCNJ2
25 long qt syndrome 3 10.8 SCN5A KCNQ1 KCNE2
26 long qt syndrome 5 10.7 SCN5A KCNQ1 KCNJ2 KCNE2
27 atrial standstill 10.7 SCN5A NPPA GJA5
28 complete atrioventricular canal-ventricle hypoplasia syndrome 10.7 GATA6 GATA4
29 long qt syndrome 6 10.7 SCN5A KCNQ1 KCNJ2 KCNE2
30 partial atrioventricular canal 10.7 GATA6 GATA4
31 andersen cardiodysrhythmic periodic paralysis 10.7 SCN5A KCNQ1 KCNJ2 KCNE2
32 familial progressive cardiac conduction defect 10.7 SCN5A NKX2-5
33 long qt syndrome 2 10.7 SCN5A KCNQ1 KCNJ2 KCNE2
34 intrinsic cardiomyopathy 10.7 SCN5A KCNQ1 KCNJ2 KCNE2
35 first-degree atrioventricular block 10.7 SCN5A GJA5
36 long qt syndrome 13 10.7 SCN5A KCNQ1
37 heart conduction disease 10.7 SCN5A KCNQ1 KCNJ2 KCNA5 GJA5
38 third-degree atrioventricular block 10.6 SCN5A KCNE2
39 mitral valve stenosis 10.6
40 transposition of the great arteries 10.5 NKX2-5 GATA5
41 atrioventricular septal defect 10.5 NKX2-5 GATA6 GATA4
42 double outlet right ventricle 10.5 NKX2-5 GATA6 GATA4
43 brugada syndrome 1 10.5 SCN5A KCNA5
44 right bundle branch block 10.5 SCN5A SCN3B SCN2B
45 patent foramen ovale 10.5 NKX2-5 GATA6 GATA4
46 pulmonary valve stenosis 10.5 SCN5A GATA4
47 ventricular septal defect 10.5 NKX2-5 GATA6 GATA5 GATA4
48 rheumatic heart disease 10.4
49 congestive heart failure 10.3
50 pulmonary valve disease 10.3 GATA6 GATA4

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 171)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Amyloidosis Anemia, Autoimmune Hemolytic
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Aortic Valve Insufficiency Asbestosis
Asthma Atrial Tachyarrhythmia with Short Pr Interval
Atrioventricular Block Bacteremia 2
Basilar Artery Insufficiency Benign Essential Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Chronic Intestinal Vascular Insufficiency Chronic Pulmonary Heart Disease
Chronic Rheumatic Pericarditis Chronic Ulcer of Skin
Colorectal Cancer Congenital Aortic Valve Insufficiency
Conjunctivitis Constrictive Pericarditis

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation

Symptoms & Phenotypes for Familial Atrial Fibrillation

UMLS symptoms related to Familial Atrial Fibrillation:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 homeostasis/metabolism MP:0005376 9.77 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNE2
3 digestive/alimentary MP:0005381 9.76 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 muscle MP:0005369 9.36 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2

Drugs & Therapeutics for Familial Atrial Fibrillation

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 509)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
6
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
7
carbamide peroxide Approved Phase 4 124-43-6
8
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
9
Atorvastatin Approved Phase 4 134523-00-5 60823
10
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
11
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
13
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
14
Sodium citrate Approved, Investigational Phase 4 68-04-2
15
Dalteparin Approved Phase 4 9005-49-6
16
Propranolol Approved, Investigational Phase 4 525-66-6 4946
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Ezetimibe Approved Phase 4 163222-33-1 150311
19
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
20
Nifedipine Approved Phase 4 21829-25-4 4485
21
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
22
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
23
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
24
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
25
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
26
Ramipril Approved Phase 4 87333-19-5 5362129
27
Histamine Approved, Investigational Phase 4 51-45-6 774
28
Antazoline Approved Phase 4 91-75-8 2200
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
31
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
32
Terazosin Approved Phase 4 63590-64-7 5401
33
Pantoprazole Approved Phase 4 102625-70-7 4679
34
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
35
Dipyridamole Approved Phase 4 58-32-2 3108
36
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
37
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
38
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
39
Nitric Oxide Approved Phase 4 10102-43-9 145068
40 Bemiparin Approved, Investigational Phase 4 91449-79-5
41
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
42
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
43
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
44
Cefpirome Approved Phase 4 84957-29-9 5479539
45
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
46
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
47
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
48
Polyestradiol phosphate Approved Phase 4 28014-46-2
49
Norethindrone Approved Phase 4 68-22-4 6230
50
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883

Interventional clinical trials:

(show top 50) (show all 2650)
# Name Status NCT ID Phase Drugs
1 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
2 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
3 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
4 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
5 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
6 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
7 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
8 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
9 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
10 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
11 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
12 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
13 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
14 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
15 Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT Unknown status NCT00959205 Phase 4
16 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
17 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
18 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
19 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
20 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
21 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
22 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
23 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
24 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
25 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
26 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
27 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
28 "Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter Unknown status NCT02217657 Phase 4
29 Relationship Between Catheter Contact Force and Electrogram Characteristics in Fibrillating Human Atrial Myocardium Unknown status NCT01587404 Phase 4
30 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
31 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
32 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
33 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
34 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
35 AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase Unknown status NCT02341105 Phase 4 Amiodarone
36 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
37 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
38 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
39 Comparison of Acute Pulmonary Vein (PV) Reconnection Between Contact Force Guided and Blinded PV Isolation in Patients With Symptomatic Atrial Fibrillation Unknown status NCT02924181 Phase 4
40 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
41 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
42 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
43 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
44 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
45 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
46 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
47 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
48 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
49 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
50 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 72 / NDF-RT 51 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Genetic Tests for Familial Atrial Fibrillation

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 29

Anatomical Context for Familial Atrial Fibrillation

MalaCards organs/tissues related to Familial Atrial Fibrillation:

41
Heart, Testes, Brain, Lung, Kidney, Endothelial, Bone

Publications for Familial Atrial Fibrillation

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 101)
# Title Authors PMID Year
1
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 9 38
18929244 2008
2
Cardiac sodium channel mutation in atrial fibrillation. 9 38
18088563 2008
3
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 9 38
17467630 2007
4
Atrial fibrillation in KCNE1-null mice. 9 38
15947250 2005
5
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 9 38
15368194 2004
6
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 9 38
12522251 2003
7
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 38
31077706 2019
8
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 38
30866607 2019
9
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 38
30558760 2019
10
Molecular Insights into the Short QT Syndrome. 38
31355049 2018
11
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 38
30443179 2018
12
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 38
28485191 2017
13
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 38
28677534 2017
14
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. 38
27742809 2017
15
Prognosis in Familial Atrial Fibrillation. 38
27866163 2016
16
Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 38
27866162 2016
17
A novel nonsense mutation in LMNA gene identified by Exome Sequencing in an atrial fibrillation family. 38
27373676 2016
18
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. 38
27261823 2016
19
Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. 38
27261827 2016
20
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 38
27066836 2016
21
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. 38
25410959 2015
22
NKX2-6 mutation predisposes to familial atrial fibrillation. 38
25319568 2014
23
TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. 38
24925317 2014
24
Whole-exome sequencing in familial atrial fibrillation. 38
24727801 2014
25
Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. 38
24648383 2014
26
KCNE2 modulates cardiac L-type Ca(2+) channel. 38
24681347 2014
27
In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. 38
24411289 2014
28
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. 38
24395921 2014
29
A novel PITX2c loss-of-function mutation associated with familial atrial fibrillation. 38
24333117 2014
30
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. 38
24006450 2013
31
Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. 38
23611745 2013
32
Characteristics of atrial fibrillation and comorbidities in familial atrial fibrillation. 38
23551519 2013
33
Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation. 38
23604097 2013
34
A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 38
23525379 2013
35
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. 38
23350853 2013
36
A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. 38
23497314 2013
37
Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. 38
23255276 2013
38
[KCNQ1 mutation in patients with lone atrial fibrillation]. 38
23651960 2013
39
Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. 38
23710137 2013
40
Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. 38
23295592 2012
41
Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. 38
22824924 2012
42
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 38
22818067 2012
43
Pro-arrhythmogenic effects of the S140G KCNQ1 mutation in human atrial fibrillation - insights from modelling. 38
22508963 2012
44
Mutational spectrum of the GATA5 gene associated with familial atrial fibrillation. 38
22483626 2012
45
Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. 38
22471742 2012
46
The role of atrial natriuretic peptide in modulating cardiac electrophysiology. 38
22083030 2012
47
Prevalence and spectrum of GATA6 mutations associated with familial atrial fibrillation. 38
22257684 2012
48
Characterization of KCNQ1 atrial fibrillation mutations reveals distinct dependence on KCNE1. 38
22250012 2012
49
Potassium-channel mutations and cardiac arrhythmias--diagnosis and therapy. 38
22290238 2012
50
Overlapping cardiac phenotype associated with a familial mutation in the voltage sensor of the KCNQ1 channel. 38
22613981 2012

Variations for Familial Atrial Fibrillation

ClinVar genetic disease variations for Familial Atrial Fibrillation:

6 (show top 50) (show all 262)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MYL4 NM_001002841.1(MYL4): c.31G> A (p.Glu11Lys) single nucleotide variant Pathogenic rs886037778 17:45286819-45286819 17:47209453-47209453
2 KCNQ1 NM_000218.2(KCNQ1): c.1875C> T (p.Pro625=) single nucleotide variant Conflicting interpretations of pathogenicity rs112113213 11:2869077-2869077 11:2847847-2847847
3 KCNA5 NM_002234.4(KCNA5): c.898G> A (p.Gly300Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs148708451 12:5154211-5154211 12:5045045-5045045
4 KCNA5 NM_002234.4(KCNA5): c.1150G> A (p.Gly384Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs76708779 12:5154463-5154463 12:5045297-5045297
5 KCNJ2 NM_000891.2(KCNJ2): c.1229A> G (p.Asn410Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs141069645 17:68172409-68172409 17:70176268-70176268
6 KCNQ1 NM_000218.2(KCNQ1): c.-5T> C single nucleotide variant Conflicting interpretations of pathogenicity rs532941548 11:2466324-2466324 11:2445094-2445094
7 ABCC9 NM_005691.3(ABCC9): c.2770-13A> G single nucleotide variant Conflicting interpretations of pathogenicity rs184123387 12:22001193-22001193 12:21848259-21848259
8 ABCC9 NM_005691.3(ABCC9): c.2199-6T> C single nucleotide variant Conflicting interpretations of pathogenicity rs535477725 12:22017417-22017417 12:21864483-21864483
9 KCNQ1 NM_000218.2(KCNQ1): c.1514+3G> A single nucleotide variant Conflicting interpretations of pathogenicity rs374767819 11:2683314-2683314 11:2662084-2662084
10 KCNQ1 NM_000218.2(KCNQ1): c.1514+9C> T single nucleotide variant Conflicting interpretations of pathogenicity rs770840921 11:2683320-2683320 11:2662090-2662090
11 KCNQ1 NM_000218.2(KCNQ1): c.1251+13C> T single nucleotide variant Conflicting interpretations of pathogenicity rs201364493 11:2608935-2608935 11:2587705-2587705
12 ABCC9 NM_005691.3(ABCC9): c.-11T> C single nucleotide variant Conflicting interpretations of pathogenicity rs72559432 12:22089619-22089619 12:21936685-21936685
13 KCNJ2 NM_000891.2(KCNJ2): c.-228C> T single nucleotide variant Conflicting interpretations of pathogenicity rs765064661 17:68165831-68165831 17:70169690-70169690
14 ABCC9 NM_005691.3(ABCC9): c.2644-11G> A single nucleotide variant Conflicting interpretations of pathogenicity rs61926078 12:22005167-22005167 12:21852233-21852233
15 ABCC9 NM_005691.3(ABCC9): c.1165-19dup duplication Conflicting interpretations of pathogenicity rs35857705 12:22063252-22063252 12:21910318-21910318
16 ABCC9 NM_005691.3(ABCC9): c.1557G> A (p.Glu519=) single nucleotide variant Conflicting interpretations of pathogenicity rs143346402 12:22059121-22059121 12:21906187-21906187
17 ABCC9 NM_005691.3(ABCC9): c.2862C> T (p.Asp954=) single nucleotide variant Conflicting interpretations of pathogenicity rs2291550 12:22001088-22001088 12:21848154-21848154
18 ABCC9 NM_005691.3(ABCC9): c.372T> C (p.Asn124=) single nucleotide variant Conflicting interpretations of pathogenicity rs377384557 12:22078910-22078910 12:21925976-21925976
19 ABCC9 NM_005691.3(ABCC9): c.407-14C> A single nucleotide variant Conflicting interpretations of pathogenicity rs201279882 12:22070051-22070051 12:21917117-21917117
20 KCNQ1 NM_000218.2(KCNQ1): c.1189C> T (p.Arg397Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs199472776 11:2608860-2608860 11:2587630-2587630
21 KCNQ1 NM_000218.2(KCNQ1): c.1179G> T (p.Lys393Asn) single nucleotide variant Conflicting interpretations of pathogenicity rs12720457 11:2608850-2608850 11:2587620-2587620
22 ABCC9 NM_005691.3(ABCC9): c.2826T> C (p.Tyr942=) single nucleotide variant Conflicting interpretations of pathogenicity rs141025897 12:22001124-22001124 12:21848190-21848190
23 ABCC9 NM_005691.3(ABCC9): c.1332C> T (p.Gly444=) single nucleotide variant Conflicting interpretations of pathogenicity rs369830406 12:22061134-22061134 12:21908200-21908200
24 KCNQ1 NM_000218.2(KCNQ1): c.387-7C> T single nucleotide variant Conflicting interpretations of pathogenicity rs201682200 11:2549151-2549151 11:2527921-2527921
25 ABCC9 NM_005691.3(ABCC9): c.1659+10T> C single nucleotide variant Conflicting interpretations of pathogenicity rs201753781 12:22048199-22048199 12:21895265-21895265
26 KCNA5 NM_002234.4(KCNA5): c.180G> A (p.Ala60=) single nucleotide variant Conflicting interpretations of pathogenicity rs376660949 12:5153493-5153493 12:5044327-5044327
27 KCNA5 NM_002234.4(KCNA5): c.1210C> T (p.Leu404=) single nucleotide variant Uncertain significance rs886049576 12:5154523-5154523 12:5045357-5045357
28 KCNA5 NM_002234.4(KCNA5): c.*50G> A single nucleotide variant Uncertain significance rs368484048 12:5155205-5155205 12:5046039-5046039
29 KCNE2 NM_172201.1(KCNE2): c.-85G> A single nucleotide variant Uncertain significance rs41315511 21:35736378-35736378 21:34364079-34364079
30 KCNE2 NM_172201.1(KCNE2): c.-80C> T single nucleotide variant Uncertain significance rs566735365 21:35736383-35736383 21:34364084-34364084
31 KCNJ2 NM_000891.2(KCNJ2): c.-258C> T single nucleotide variant Uncertain significance rs886053321 17:68165801-68165801 17:70169660-70169660
32 KCNJ2 NM_000891.2(KCNJ2): c.-88C> T single nucleotide variant Uncertain significance rs886053322 17:68171093-68171093 17:70174952-70174952
33 KCNJ2 NM_000891.2(KCNJ2): c.*122G> A single nucleotide variant Uncertain significance rs886053324 17:68172586-68172586 17:70176445-70176445
34 KCNJ2 NM_000891.2(KCNJ2): c.*1412G> A single nucleotide variant Uncertain significance rs886053331 17:68173876-68173876 17:70177735-70177735
35 KCNJ2 NM_000891.2(KCNJ2): c.*1702_*1704dup duplication Uncertain significance rs1555604193 17:68174166-68174168 17:70178025-70178027
36 KCNJ2 NM_000891.2(KCNJ2): c.*1720_*1721dup duplication Uncertain significance rs35753731 17:68174184-68174185 17:70178043-70178044
37 KCNJ2 NM_000891.2(KCNJ2): c.*1721dup duplication Uncertain significance rs35753731 17:68174185-68174185 17:70178044-70178044
38 KCNJ2 NM_000891.2(KCNJ2): c.*2698T> C single nucleotide variant Uncertain significance rs368668294 17:68175162-68175162 17:70179021-70179021
39 KCNJ2 NM_000891.2(KCNJ2): c.*2754T> C single nucleotide variant Uncertain significance rs9915769 17:68175218-68175218 17:70179077-70179077
40 ABCC9 NM_005691.3(ABCC9): c.1165-7_1165-6del deletion Uncertain significance rs35857705 12:22063252-22063253 12:21910318-21910319
41 ABCC9 NM_005691.3(ABCC9): c.669G> T (p.Leu223=) single nucleotide variant Uncertain significance rs17846788 12:22068749-22068749 12:21915815-21915815
42 ABCC9 NM_005691.3(ABCC9): c.146G> C (p.Trp49Ser) single nucleotide variant Uncertain significance rs886049175 12:22086854-22086854 12:21933920-21933920
43 KCNA5 NM_002234.4(KCNA5): c.*782G> A single nucleotide variant Uncertain significance rs189015926 12:5155937-5155937 12:5046771-5046771
44 ABCC9 NM_005691.3(ABCC9): c.3669+10T> C single nucleotide variant Uncertain significance rs199640712 12:21981882-21981882 12:21828948-21828948
45 ABCC9 NM_005691.3(ABCC9): c.466T> C (p.Cys156Arg) single nucleotide variant Uncertain significance rs886049173 12:22069978-22069978 12:21917044-21917044
46 KCNA5 NM_002234.4(KCNA5): c.847C> T (p.Arg283Cys) single nucleotide variant Uncertain significance rs886049575 12:5154160-5154160 12:5044994-5044994
47 KCNA5 NM_002234.4(KCNA5): c.*493A> G single nucleotide variant Uncertain significance rs886049577 12:5155648-5155648 12:5046482-5046482
48 KCNJ2 NM_000891.2(KCNJ2): c.*1702_*1703CT[3] short repeat Uncertain significance rs1555604187 17:68174168-68174169 17:70178027-70178028
49 KCNJ2 NM_000891.2(KCNJ2): c.*2001A> G single nucleotide variant Uncertain significance rs886053336 17:68174465-68174465 17:70178324-70178324
50 KCNJ2 NM_000891.2(KCNJ2): c.*2770_*2775del deletion Uncertain significance rs35656864 17:68175234-68175239 17:70179093-70179098

Expression for Familial Atrial Fibrillation

Search GEO for disease gene expression data for Familial Atrial Fibrillation.

Pathways for Familial Atrial Fibrillation

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.42 SCN5A SCN4B SCN3B SCN2B NPPA NKX2-5
2
Show member pathways
12.41 NKX2-5 GATA6 GATA5 GATA4
3 12.15 KCNQ1 KCNJ2 KCNE2 KCNA5
4 11.97 SCN5A SCN4B SCN3B KCNQ1
5
Show member pathways
11.83 SCN5A SCN4B SCN3B SCN2B
6
Show member pathways
11.51 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNE2
7 11.38 SCN5A NKX2-5 GATA4
8 11.34 MYL4 GATA6 GATA4
9 11.33 PITX2 NKX2-5 GATA6 GATA4
10 11.03 SCN5A SCN4B SCN3B SCN2B
11 11.02 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
12 10.92 NPPA NKX2-5 GATA4
13 10.8 KCNQ1 KCNJ2
14 10.28 NPPA NKX2-5 GATA4

GO Terms for Familial Atrial Fibrillation

Cellular components related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.46 KCNQ1 KCNJ2 KCNE2 KCNA5
2 Z disc GO:0030018 9.43 SCN5A SCN3B KCNA5
3 voltage-gated sodium channel complex GO:0001518 9.26 SCN5A SCN4B SCN3B SCN2B
4 intercalated disc GO:0014704 9.02 SCN5A SCN4B KCNJ2 KCNA5 GJA5

Biological processes related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 potassium ion transport GO:0006813 9.97 KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
2 sodium ion transport GO:0006814 9.95 SCN5A SCN4B SCN3B SCN2B
3 potassium ion transmembrane transport GO:0071805 9.94 KCNQ1 KCNJ2 KCNE2 KCNA5
4 regulation of ion transmembrane transport GO:0034765 9.92 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
5 sodium ion transmembrane transport GO:0035725 9.91